Drug or Treatment Category: Therapeutic Antibody

NCT05489211: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours

NCT05489211
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor, Chemotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have at least one target lesion that has not previously received radiation therapy
Exclusions: Patients with untreated brain metastases; Patients with leptomeningeal disease; Patients that have received prior treatment of a TROP2-directed antibody-drug conjugate (e.g. datopotamab deruxtecan , Trodelvy/sacituzumab govitecan) or other ADC with deruxtecan payload (e.g. Enhertu/Trastuzumab deruxtecan)
https://ClinicalTrials.gov/show/NCT05489211

NCT05468359: Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

NCT05468359
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: up to 30 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Part 1 of the study
Exclusions: Patients over the age of 30 years; Patients with tumors not safely accessible by biopsy
https://ClinicalTrials.gov/show/NCT05468359

Up ↑